Clinical trial
Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in…
NCT00000809 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Withdrawn
Key facts
| NCT number | NCT00000809 |
|---|---|
| Title | Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women |
| Official title | A Phase I Trial of the Safety and Immunogenicity of MN rsgp120/HIV-1 With the Adjuvants QS-21 and Alum Compared to MN rsgp120/HIV-1 and QS-21 in Infants Born to HIV-Infected Women |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections, HIV Seronegativity |
| Intervention type | Biological |
| Interventions | Aluminum hydroxide, QS-21, MN rsgp120/HIV-1 |
| Enrollment | 0 |
| First posted | Aug 31, 2001 |
| Last update posted | Oct 29, 2021 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: